



Strategy Description

Meranti Millennium Equity Fund 'MME' seeks long-term high growth of the portfolio by investing opportunistically across global equity markets, while looking to mitigate risks during significant downturns. Instead of investing in flavour of the day concepts, the strategy focuses on key performance drivers that make sense and are backed by empirical research.

Key Features


Dynamic Risk Mitigation: Financial crises are infrequent but inevitable. By managing risks in significant downturns, the strategy is designed to help investors endure systemic market shocks and continue to invest with confidence.

High Return Potential: Capture ongoing opportunities by taking advantage of market volatility to invest into attractive equity markets with high expected returns.


Active Strategy: Markets exhibit trends and cycles that create ongoing opportunities to invest in. Using Fundamental, Valuation, and Technical principles; we aim to invest into differentiated markets with favourable risk/reward that can deliver long-term outperformance.

Global Equities Invest into attractive equity opportunities globally Dynamic Risk Mitigation Risk management to mitigate risk of negative compounding Global Equities Cythamic Risk Mitigation Risk management to mitigate risk of negative compounding

Geographical Breakdown



Market Breakdown



Top 5 Fund Holdings

Fund Name	
Aberdeen China 'A' Shares Fund	
Amundi European Equity Value Fund	
Blackrock World Healthscience Fund	
Granahan US SMID Select Fund	
TT Emerging Market Unconstrained Fund	

Portfolio Statistics*

	Portfolio
Average Month	1.5%
Best Month	13.8%
Worst Month	-9.7%
Positive Months	69.4%

'For illustrative purposes only. Calculated from 1/8/2018 using a similarly managed composite portfolio fully invested gross of fees. Performance since 1/4/2021 is based on actual fund performance before any management and performance fees. Portfolio statistics may not be a good indication of actual performance which can differ meaningfully over shorter time periods.

Monthly Performance History

2021	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD ²
SGD A	-	-	-	2.30%	1.98%	0.76%	-5.31% ¹						-0.47%1
USD B	_	-	-	1.95%	1.62%	0.77%	-5.26% ¹						-1.09%1

¹Manager's estimated return net of fees for each respective class. Actual return may differ and will be updated in the following month. Please reach out to your advisor to find out about the longer strategy track record. ²YTD refers to performance since inception.

IMPORTANT NOTICE & DISCLAIMERS

The information herein is given on a general basis without obligation and is strictly for information only. This publication is not an offer, solicitation, recommendation or advice to buy or sell any investment product, including any collective investment schemes or shares of companies mentioned within. Although every reasonable care has been taken to ensure the accuracy, timeliness and objectivity of the information contained in this publication, Finexis Asset Management Pte. Ltd. and its employees cannot be held liable for any errors, inaccuracies and/or omissions, howsoever caused, or for any decision or action taken based on views expressed or information in this publication. The value of shares values in the Fund and income there from (if any) may fall or rise. Past performance is not an indication of future performance. Investment in the Fund is subject to investment risks, including the possible loss of all or a substantial portion of the principal amount invested. Investors interested in the Fund should read the Private Placement Memorandum (PPM) and seek relevant professional advice before deciding whether to invest in the Fund. Should you choose not to seek such advice, you should consider whether the Fund is suitable for you.





Market & Portfolio Developments

Market Review

Emerging Markets took a major hit in July as the Chinese government clampdown on certain industries and companies reverberated across markets. China 'A' markets were down 7.3%, and the broader emerging markets dropped 6.7% in sympathy.

Main Contributors 'What did well'?

Healthcare equities (part of the stability theme) contributed positively, performing as we expect in volatile markets. Positions in Europe equities also helped, as they were more resilient than EM positions, and continued to be supported by strong economic activity. The past month's contributors highlight the importance of diversification which is especially evident during market stress.

Main Detractors 'What underperformed?'

Concerns around the Chinese government clampdown caused contagion effects which led to meaningful declines in our China 'A' and Emerging Markets positions. Looking beyond near-term concerns, both markets continue to trade at reasonable valuations (in particular to the richly-valued DM markets) and where earnings are expected to continue to benefit from the ongoing global recovery. We also take comfort that Chinese policy markets have taken steps to calm investors more recently.

Portfolio Activity

Amid market volatility, the focus was on maintaining the integrity of our portfolio allocations.

Market Outlook

The litany of regulations imposed by the Chinese government is yet another of a string of events this year that has led to bouts of volatility and risk-off behaviour amongst investors. In such an environment, we continue to stick to our FVT process to invest in opportunities with better margin of safety and with better risk/reward – this results in a forward-looking portfolio that is expected to have higher future returns. Our long-time investors know that this may result in short-term deviations in performance to peers and benchmarks (which tend to be US heavy), but result in a more rewarding journey for us in the end.

Fund Details

Item	Class A	Class B				
Currency	USD, SGD					
ISIN (USD Class)	SGXZ35636000 (Distribution)	SGXZ56727852 (Accumulation)				
ISIN (SGD Class)	SGXZ32206252 (Distribution)	SGXZ53567772 (Accumulation)				
Projected Distribution ³	4% p.a.	-				
Min. Subscription	USD 400,000 SGD 500,000	USD 40,000 SGD 50,000				
Account Opening Fee (One-time)	N/A	USD 3,000 SGD 4,000				
Min. Subsequent Subscription	USD 10,000 SGD 15,000	USD 10,000 SGD 15,000				
Redemption Fees						
1st Year of Investment	-	3%				
2nd Year of Investment	-	2%				
3rd Year of Investment	-	1%				
4th Year Onwards	-	0%				
Management Fee	1.78%	0%				
Performance Fee ⁴	0%	20%				
Fund Name		apital VCC Equity Fund				
Dealing Frequency	Mor	nthly				
Base Currency	Us	USD				
Inception Date	1 Apri	1 April 2021				
Fund Domicile	Singa	Singapore				
Investment Manager	Finexis Asset Management					
Fund Administrator		ASCENT Fund Services (Singapore)				
Custodian	<u> </u>	Standard Chartered Bank				
Auditor	KPM0	KPMG LLP				
Broker	Goldman Sachs (Asia) L.L.C.					
Legal Advisors	BTPLaw LLC					

³ Please note that the distributions (if any) may be declared semi-annually based on the Investment Manager's discretion. If distributions are made, such distributions are not a forecast, indication or projection of the future performance of the Fund. ⁴ Charged on high water mark basis, with zero hurdle rate.

About **Meranti**: The Meranti fund series is named after the Meranti tree, which is native to Singapore and the region. It is a canopy and emergent tree; providing shade from its place at the top layer of a rainforest where sunlight is plentiful. To reach such great heights, the trees have a strong and wide system of roots to help provide stability while also gathering more nutrients. Likewise, Meranti funds were developed around a Dynamic Risk Mitigation process so that investors can invest with confidence and harvest the full potential of capital growth through market cycles.

About **FAM**: Finexis Asset Management is a Capital Markets Services (CMS) licensed fund management company established in Singapore, focusing on bringing institutional capabilities to private clients. The boutique set-up ensures that we are flexible, responsive and proactive. We embrace the latest technology and constantly improve our processes to complement our investment solutions. Constant evolution to fulfil our investor's needs is ingrained in our beliefs.

For fund and sales related enquires please reach out to your finexis financial advisor representative or email us at customer.service@finexisam.com

IMPORTANT NOTICE & DISCLAIMERS

The information herein is given on a general basis without obligation and is strictly for information only. This publication is not an offer, solicitation, recommendation or advice to buy or sell any investment product, including any collective investment schemes or shares of companies mentioned within. Although every reasonable care has been taken to ensure the accuracy, timeliness and objectivity of the information contained in this publication, Finexis Asset Management Pte. Ltd. and its employees cannot be held liable for any errors, inaccuracies and/or omissions, howsoever caused, or for any decision or action taken based on views expressed or information in this publication. The value of shares values in the Fund and income there from (if any) may fall or rise. Past performance is not an indication of future performance. Investment in the Fund is subject to investment risks, including the possible loss of all or a substantial portion of the principal amount invested. Investors interested in the Fund should read the Private Placement Memorandum (PPM) and seek relevant professional advice before deciding whether to invest in the Fund. Should you choose not to seek such advice, you should consider whether the Fund is suitable for you.